An FDA warning letter is a formal written notice from the U.S. Food and Drug Administration to a firm that documents violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations. It is the agency's principal enforcement instrument short of litigation: a warning letter puts a company on official notice, demands a written corrective response, and becomes a permanent public record in the FDA Warning Letters database. For e-liquid brand owners and flavor concentrate buyers, the practical significance is immediate — a supplier with a citation history can trigger import detentions, destabilize your own compliance files, and complicate a premarket tobacco product application (PMTA) or substantial-equivalence strategy.The Center for Tobacco Products (CTP) issues the flavor-relevant warning letters that matter most to e-liquid manufacturers, but the flavor industry also sits inside the FDA's food program. A single concentrate can serve a beverage line, a bakery application, and an e-liquid base at the same time, which means a flavor house can face citations under tobacco rules, food-additive rules, and labeling rules administered by different FDA centers. This article walks through the citation categories that actually appear in FDA warning letters, the verified regulatory facts behind each category, and the documentation you should demand from any flavor concentrate supplier that feeds a U.S. product line.If your brand is pursuing premarket authorization, the quality of the supplier's flavor documentation is decisive. Our PMTA flavor master files support program 解释了如何整合完整成分披露、批量 GC-MS 数据、热稳定性分析和毒理学摘要以供 FDA 审查——相同的文档基线使配方不符合下述引用模式。
FDA 警告信：电子烟油品牌常见的与风味相关的引文
FDA 警告信计划如何运作
从检查到公共记录
Warning letters usually begin with a facility inspection, an import examination, or a desk review of a company's own website, labeling, and advertising. During a facility inspection, FDA investigators record observations on a Form FDA 483, which the firm has an opportunity to address before the agency decides whether a warning letter is warranted. When FDA concludes that violations exist, it issues a letter signed by the issuing office — in the tobacco space, typically the Office of Compliance and Enforcement at the Center for Tobacco Products — and posts it publicly in the FDA Warning Letters database, where it remains searchable by company name, product type, and issue date.The database is free and public, and it is the first due-diligence screen any buyer should run on a flavor supplier. Search the supplier's legal name, its trade names, and the names of affiliated brands. A clean record is not a certification of compliance, but a citation history — particularly repeated citations across years — is a documented pattern of regulatory risk that will eventually reach your products.
15 个工作日的响应窗口和升级风险
FDA warning letters routinely require a written response within 15 working days of receipt, describing corrective actions, the dates on which violative products were discontinued, and a plan for maintaining compliance. In FDA's August 8, 2019 action against four companies selling 44 flavored e-liquid and hookah tobacco products, the agency explicitly requested responses within 15 working days, including discontinuation dates and future-compliance plans. Failure to respond adequately escalates enforcement to civil money penalty complaints, product seizure, or injunction, and adulterated or misbranded products offered for import may be detained or refused admission at the border.两个结构性事实使该程序异常引人注目。首先，警告信是永久性的公开文件，因此它们会影响经销商的尽职调查、保险承保和平台列表多年。其次，FDA 不需要等待检查：很大一部分引用来自审查营销网站的机构，这就是为什么产品页面和社交渠道上的语言是监管证据。
引文类别 1：未经上市前授权营销新烟草产品
谓词日期和推定规则
The most common flavor-related citation in the e-liquid industry is not about the flavor chemistry at all — it is about the absence of marketing authorization for the flavored product. Under the Tobacco Control Act of 2009, any tobacco product that was not commercially marketed in the United States as of February 15, 2007 is a new tobacco product requiring a marketing authorization order under 21 U.S.C. § 387j(c)(1)(A)(i), unless it qualifies for a substantial-equivalence exemption under § 387e(j). E-liquids and their components became subject to FDA jurisdiction through the deeming rule in 21 CFR Part 1100, finalized in 2016, and FDA treats products introduced or modified after the rule's effective date as unauthorized unless they hold the required authorization.A new tobacco product without authorization is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)) and misbranded under section 903(a)(6) (21 U.S.C. § 387c(a)(6)), and the acts of selling or holding such a product for sale after interstate shipment are prohibited acts under section 301(k) and 301(p). These statutory citations appear verbatim in FDA's e-liquid warning letters, which is why regulatory counsel reads them as a checklist: marketing authorization status, substantial-equivalence report status, and documentation of the product's predicate lineage.
一个典型的例子：Vixen Vapor 警告信
A concrete, verifiable example is the warning letter FDA issued to Vixen Vapors LLC d/b/a Vixen Vapors Pantego on February 15, 2024 (Reference ER2401014), delivered by UPS and electronic mail. FDA's Center for Tobacco Products determined that the firm manufactured and distributed e-liquid for commercial distribution in the United States without a marketing authorization order, naming the product Vixen Vapors Pompeii 14mg 120ml in the letter. FDA explained that the product is adulterated under 21 U.S.C. § 387b(6)(A) and misbranded under 21 U.S.C. § 387c(a)(6), and reminded the firm that the Consolidated Appropriations Act, 2022 (Public Law 117-103, Division P, Title I, Subtitle B), signed March 15, 2022, extended FDA jurisdiction to products containing nicotine from any source — including synthetic nicotine that is not derived from tobacco.该信函最后提出了标准的 15 个工作日回复要求，并警告称，持续违规可能会导致民事罚款、扣押或禁令，违规进口货物可能会被扣留或拒绝入境。对于买家来说，这个教训是具体的：您的产品组合中的每个风味 SKU 都必须追溯到可防御的营销授权地位，而您持有的浓缩香料文档是该地位的一部分。
这对浓缩香料买家意味着什么
如果您从香料公司购买浓缩液并自己配制成品电子烟油，您将继承成品的监管负担。即使是单一的水果味系列，例如我们的 cherry-flavor concentrate range must be backed by complete compound-level documentation, because FDA evaluates the finished product's components — flavor compounds, carriers, and additives — when it reviews a PMTA or inspects your facility. A supplier that cannot produce ingredient data on request is a compliance liability, not a cost saving.
通过 FDA 检查的风味文件：GC-MS、FIDO 和 COA
引文类别 2：调味产品和 2020 年执法重点
2020 年 4 月实践指南
FDA's guidance document Enforcement Priorities for Electronic Nicotine Delivery System (ENDS) and Other Deemed Products on the Market Without Premarket Authorization (April 2020; Docket FDA-2019-D-0661) tells companies exactly where enforcement will concentrate. The agency announced that it intends to prioritize enforcement for lack of marketing authorization against any flavored, cartridge-based ENDS product other than a tobacco- or menthol-flavored product; against ENDS products that are targeted to minors, whether directly or through media; and against ENDS products whose labeling or advertising causes them to be marketed as modified-risk tobacco products without an FDA order. Flavor is therefore not a side issue — the flavor profile is the defining characteristic that places a product in the priority enforcement tier.The guidance's three priority categories map directly onto the flavor supply chain. A fruit-, candy-, or dessert-flavored cartridge product sits in tier one; a product whose packaging or marketing resembles kid-friendly food or beverage items sits in tier two; and any marketing language implying reduced harm without an FDA modified-risk order sits in tier three. Every one of these categories can implicate the flavor concentrate: its identity (tier one), the label and marketing assets built around it (tier two), and the claims made about it (tier three).
执法数据：2020 年和 2021 年警告信
Published research confirms the scale and shape of the program. Schillo and colleagues, analyzing FDA warning letters sent to e-cigarette companies between January 1, 2020 and September 9, 2021 (Tobacco Control, 2024; PMID 36229228), coded 303 warning letters: 126 from 2020 and 177 from 2021. The study found that 97.4 percent of the letters went to small online retailers, 94.1 percent of the cited companies were located in the United States, 75.2 percent of the infractions were identified by reviewing a company's website, and 70.5 percent were PMTA violations. The letters cited 880 products, of which 92.2 percent were e-liquid, with 32.4 percent fruit-flavored and 31.1 percent concept-flavored.Two practical conclusions follow for flavor buyers. First, flavored e-liquid is the enforcement epicenter, which makes flavor documentation the single most requested category of evidence in the program. Second, the 2020–2021 enforcement wave concentrated on small online retailers; as that layer consolidates, importers, distributors, and manufacturers are squarely in FDA's field of view, and warning letters naming e-liquid products by name — like the Vixen Vapors letter — show how the agency tracks products through the supply chain.
风味文档是防御
针对调味产品引用的最佳防御措施是从浓缩物供应商到成品 SKU 的记录、可辩护的配方跟踪。该线索包括跨司法管辖区的附加合规数据；我们的 GB 41700-2022 additive compliance guide explains how China's national standard for e-liquid restricts the permitted additive list, a useful cross-check when the same concentrate family is dual-sourced into U.S. and Asian markets. In the U.S. system, the package of Full Ingredient Disclosure, GC-MS batch analysis, Certificates of Analysis, and Safety Data Sheets is what regulatory counsel will assemble to demonstrate good-faith diligence if FDA ever requests information or issues a letter.
21 CFR 第 117 部分 浓缩香料生产的 cGMP 合规性
引文类别 3：香料制造商收到的食品安全和标签引文
未经批准的食品添加剂和掺假
根据 FDA 食品计划，销售食品和饮料应用的浓缩香料公司面临着独特的引用系列。 21 岁以下美国法典根据第 342(a)(2)(C) 条，如果食品含有或含有第 348 条含义内的不安全食品添加剂，即合格专家不普遍认为安全 (GRAS) 的物质，并且不属于适用的食品添加剂法规、食品接触通知或事先制裁的对象，则食品被掺假。当风味成分或载体在其批准的使用条件之外使用时，FDA 可能会引用浓缩物制造商的信息，在成品中，还会引用掺入该成分或载体的配方设计师的信息。The flavor industry's own GRAS system — the Flavor and Extract Manufacturers Association (FEMA) GRAS program — provides the expert-review pathway that most flavor compounds rely on, but GRAS status is substance- and use-specific. A compound that is GRAS for food use is not automatically acceptable as an e-liquid ingredient, and FDA's PMTA review treats inhalation exposure separately from ingestion. Buyers should therefore ask for each ingredient's GRAS status, its regulatory listing under 21 CFR Parts 182, 184, and 186 where applicable, and the use-level range the supplier actually validated.
错误品牌：过敏原声明和营销声明
Misbranding citations under 21 U.S.C. § 343 are the second food-side family. A label is false or misleading under § 343(a) if it makes unsubstantiated claims, and § 343(w) requires food labels to declare major food allergens — milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, and soybeans — with sesame added effective January 1, 2023 under the FASTER Act. Flavor concentrates containing allergen-derived ingredients, such as dairy- or nut-based extracts, drive finished-product allergen declarations, and the supplier's allergen matrix is the evidence that keeps your labels compliant.In the tobacco space the misbranding analogue is just as sharp. Finished e-liquid labels must carry the required nicotine warning statement, and any labeling or advertising that implies FDA approval or registration without an order is a serious misbranding issue. FDA has repeatedly acted against firms whose packaging or marketing positioned products as FDA-approved, and the agency's enforcement-priority guidance treats modified-risk language as a priority category in its own right. Marketing copy is regulatory evidence — review it with the same discipline as the label itself.
cGMP、预防控制和设施注册
第三个食品方面系列是当前的良好生产规范 (cGMP) 和 21 CFR 第 117 部分规定的预防性控制措施，该框架是 FSMA 时代的框架，取代了旧的 21 CFR 第 110 部分规则。风味工厂必须维持 cGMP，涵盖卫生、水安全、过敏原交叉接触控制和员工卫生；在适用的情况下，他们必须实施书面食品安全计划，包括危害分析和基于风险的预防控制措施；大多数设施必须根据 21 CFR 第 1 部分 H 子部分向 FDA 注册，每两年更新一次注册。当检查发现卫生条件不合格、产品受污染或缺乏控制时，FDA 会在警告信中引用 21 CFR 117 的具体章节。For an e-liquid brand, the same GMP discipline governs the quality of the liquid you bottle: concentrate purity, microbial limits, cross-contact prevention, and clean production environments all feed the finished product's safety profile. Supplier audits should verify that the plant operates under a documented quality system — ISO 22000, HACCP, or equivalent — and that batch records tie every Certificate of Analysis to a specific production run.
合规性供应商必须提供的文件
合规性香料供应商应根据要求提供完整的文件集：化合物级完整成分披露，其中包含 CAS 编号和浓度；批次 GC-MS 色谱图证明配方一致性；每批的分析证书；安全数据表；过敏原矩阵；以及每种成分的 FEMA GRAS 或 21 CFR 状态声明。当您收到我们的浓缩水果时 blueberry-flavor concentrate line 通过此文档包，您已将商品采购转换为可供审计的监管资产。当供应商无法提供这些文件时，请将其视为您收到的第一个警告信号 - 它比 FDA 的便宜得多。
风味标签中的错误品牌风险：过敏原和营销声明
电子烟油品牌和进口商合规检查表
在签署供应协议之前，根据 FDA 警告信数据库和 FDA 进口拒绝报告筛选每个供应商。
需要每种浓缩物的化合物级成分文件（完整成分披露），包括 CAS 编号、浓度和载体溶剂。
Confirm each finished SKU's marketing-authorization status: a PMTA order, a substantial-equivalence exemption, or a documented predicate analysis.
验证风味文档是否涵盖加热状态行为——热降解产物和羰基形成是 FDA 审查人员在气溶胶数据中看到的内容。
每次发货时都需要批量 GC-MS 数据和分析证书，并在整个产品生命周期内对其进行存档。
与顾问一起审查每个标签和网站声明：未经 FDA 命令，不得使用 FDA 批准、FDA 注册或修改风险语言。
Confirm the allergen status of each flavor ingredient and carry the supplier's allergen matrix into your finished-product labels.
Audit the supplier's 21 CFR Part 117 cGMP and preventive-controls posture during qualification visits, including sanitation and cross-contact programs.
跟踪 FDA 指南更新——执行重点发生变化，2020 年指南已经从墨盒产品扩展到一次性产品和其他形式。
